|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Rosuvastatin#Drug Interactions]] |
| {{Rosuvastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
|
| |
|
| ==Drug Interactions==
| | [[Category: Cardiovascular Drugs]] |
| | | [[Category: Drug]] |
| ===Cyclosporine===
| | [[Category: Statins]] |
| | |
| [[cyclosporine]] increased rosuvastatin exposure (AUC) 7‑fold. Therefore, in patients taking [[cyclosporine]], the dose of CRESTOR should not exceed 5 mg once daily [seeDosage and Administration (2.5), Warnings and Precautions (5.1), and Clinical Pharmacology (12.3)].
| |
| | |
| ===Gemfibrozil===
| |
| | |
| [[Gemfibrozil ]]significantly increased rosuvastatin exposure. Due to an observed increased risk of [[myopathy]]/[[rhabdomyolysis]], combination therapy with CRESTOR and [[gemfibrozil]] should be avoided. If used together, the dose of CRESTOR should not exceed 10 mg once daily [see Clinical Pharmacology (12.3)].
| |
| | |
| ===Protease Inhibitors===
| |
| | |
| Coadministration of rosuvastatin with certain protease inhibitors given in combination with [[ritonavir ]]has differing effects on rosuvastatin exposure. The protease inhibitor combinations [[lopinavir]]/[[ritonavir]] and [[atazanavir]]/[[ritonavir]] increase rosuvastatin exposure (AUC) up to threefold [see Table 4 – Clinical Pharmacology (12.3)]. For these combinations the dose of CRESTOR should not exceed 10 mg once daily. The combinations of [[tipranavir]]/[[ritonavir]] or [[fosamprenavir]]/[[ritonavir]] produce little or no change in rosuvastatin exposure. Caution should be exercised when rosuvastatin is coadministered with protease inhibitors given in combination with [[ritonavir ]][see Dosage and Administration (2.5),Warnings and Precautions (5.1) andClinical Pharmacology (12.3)].
| |
| | |
| ===Coumarin Anticoagulants===
| |
| | |
| CRESTOR significantly increased INR in patients receiving coumarin [[anticoagulants]]. Therefore, caution should be exercised when coumarin [[anticoagulant]]s are given in conjunction with CRESTOR. In patients taking coumarin [[anticoagulant]]s and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].
| |
| | |
| ===Niacin===
| |
| | |
| The risk of skeletal muscle effects may be enhanced when CRESTOR is used in combination with lipid-modifying doses (≥1 g/day) of [[niacin]]; caution should be used when prescribing with CRESTOR [see Warnings and Precautions (5.1)].
| |
| | |
| ===Fenofibrate===
| |
| | |
| When CRESTOR was coadministered with [[fenofibrate]], no clinically significant increase in the AUC of rosuvastatin or [[fenofibrate]] was observed. Because it is known that the risk of [[myopathy]] during treatment with HMG-CoA reductase inhibitors is increased with concomitant use of [[fenofibrate]]s, caution should be used when prescribing [[fenofibrate]]s with CRESTOR [see Warnings and Precautions (5.1) andClinical Pharmacology (12.3)].
| |
| | |
| ===Colchicine===
| |
| | |
| Cases of [[myopathy]], including [[rhabdomyolysis]], have been reported with HMG‑CoA reductase inhibitors, including rosuvastatin, coadministered with [[colchicine]], and caution should be exercised when prescribing CRESTOR with [[colchicine]] [see Warnings and Precautions (5.1)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CRESTOR (ROSUVASTATIN CALCIUM) TABLET, FILM COATED [ASTRAZENECA PHARMACEUTICALS LP] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb0f3b5e-4bc6-41c9-66b9-6257e2513512 | publisher = | date = | accessdate = 17 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Statins}}
| |
| | |
| [[Category:Statins]] | |
| [[Category:AstraZeneca]] | |
| [[Category:Carboxylic acids]] | |
| [[Category:Sulfonamides]]
| |
| [[Category:Pyrimidines]]
| |
| [[Category:Organofluorides]]
| |